Swedish mitochondrial medicine firm NeuroVive Pharmaceutical (Nasdaq OMX: NVP) has entered into an exclusive licensing agreement with USA-based biotech BridgeBio Pharma for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program.
BridgeBio also announced that it has launched a subsidiary company Fortify Therapeutics to further develop this chemistry for local treatment of Leber's hereditary optic neuropathy (LHON), with an initial financial commitment of $20 million. NeuroVive's NVP015 program for other mitochondrial disorders will continue without any changes in focus or timelines.
The licensing agreement for this particular subset of the NVP015 program has a total deal value of around $60 million, which includes limited initial funding for research, and later milestone payments and a single digit royalty stream, that are dependent on successful development and market approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze